利多卡因在肝血管瘤介入治疗中的价值

目的 采用肝血管瘤介入治疗的不同方法,探讨利多卡因在肝血管瘤介入治疗中的价值.方法 将36例肝血管瘤病例分为两组,A组(19例)在动脉栓塞前,先经动脉灌注利多卡因,再将利多卡因与平阳霉素、碘油混合后碘油和药物的乳化剂注人;B组(17例)为对照组,动脉栓塞过程中,不用利多卡因.观察治疗过程中患者的反应和病灶碘油和药物的乳化剂的填充情况.结果 两组中重度不良反应比例不同,利多卡因组为10.5%,对照组为41.2%.病灶碘油和药物的乳化剂的完全填充率利多卡因组为100%,对照组为79.2%.结论 肝血管瘤介入治疗过程中,应用利多卡因可以提高介入治疗的成功率,降低不良反应,取得较好疗效.

Value of lidocaine in interventional therapy for liver hemangioma

Objective To investigate the value of lidocaine in interventional therapy for liver hemangioma. Methods Thirty-six patients with liver hemangioma were divided into group A (n=19) receiving lidocaine prior to transcatheter arterial embolization (TAE), then the emulsion of pingyangmycin, lidocaine and iodized oil; group B (n=17) receiving the emulsion of pingyangmycin and iodized oil except lidocaine. We observed that the reaction of all patients after TAE and how much the hemangioma was filled. Results The rate of serious complications was 10.5% in group A and 41.2% in group B. The hemangioma filling with emulsion was 100% in group A and 79.2% in group B. Conclusion Intraarterial pharmacotheraphy of lidocaine in interventional therapy for liver hemangioma may promote the chance of success and reduce serious complications, result in good effect.